Promethera Biosciences Raised €25,33M to Treat Liver Diseases

25/11/2014 - 2 minutes

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, raised 25,33 million euros.

The major innovation of Promethera HepaStem is based on Heterologous Human Adult Liver Progenitor Cells (HHALPC). It is a potential to treat a wide variety of congenital and acquired liver diseases.

The success of this Series-C fundraising is the result of the completion of the HepaStem phase I/II study, following a Series B fundraising in March 2012 when‚ 17 million in equity was raised. Promethera Biosciences has attracted two new investors in this new round, securing a third capital increase of ‚20.33 million. SFPI-FPIM, the Belgian Federal Holding and Investment Company, and SMS Investments, a Luxemburg based subsidiary office of the German SMS group are the two new investors and joined the historical international one.

In addition, the Walloon region, which has backed the company since its inception, has granted loans and subsidies of 5 million to support the clinical development of HepaStem and the collaborative program with EMD-Millipore.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following: